



Oifig an Stiúrthóra Náisiúnta Ghéarmhíocháine Straitéis agus Pleanáil
FnaSS, Ospidéal Dr. Steevens, Baile Átha Cliath 8, D08 W2A8
Tel: 01-6352232 R: acute.strategy@hse.ie

Office of National Director Acute Strategy and Planning
HSE, Dr Steevens Hospital, Dublin 8. D08 W2A8
Tel: 01-6352232 Email: acute.strategy@hse.ie

Monday, 11th March 2019

Deputy Bobby Aylward,
Dáil Eireann,
Leinster House,
Kildare Street,
Dublin 2

RE: PQ Ref: 9860/19 – To ask the Minister for Health the reimbursement status of the drug Fasentra (benralizumab); if it has been discussed by the HSE Drugs Leadership Group; and if he will make a statement on the matter.

PQ Ref: 9861/19 - To ask the Minister for Health if a decision has been made on the reimbursement of the drug Fasentra (benralizumab) by the HSE Drugs Leadership Group; when he expects it to be made available to patients; and if he will make a statement on the matter.

Dear Deputy Aylward,

The Health Service Executive (HSE) has been requested to reply directly to you in the context of the above Parliamentary Questions, which you submitted to the Minister for response.

The application for Benralizumab was considered at the January 2019 Leadership Team meeting and was approved for reimbursement. The company is being contacted to finalise the implementation arrangements for reimbursement.

I trust the above information is of assistance to you.

Yours sincerely,

John Hennessy
National Director
Acute Strategy & Planning